Moderna finally proves it has a post-Covid vaccine life
Can you say rollercoaster? In 2022, the biotech company generated sales of nearly $18.9 billion, all of it from sales of its Covid-19 vaccine but it expects revenue of only $4 billion this year. On February 14, 2023, shares sold for $175.62. On $86.04 on February 14,...
Counter-counter-attack from Viking Therapeutics in the GLP-1 diabetes/weight loss drug war
First, it was Viking Therapeutics (VKTX) on the attack with trial results that showed its GLP-1 diabetes/weight loss drug out performing current leader of the pack drugs from Novo Nordisk (NVO) and Eli Lilly (LLY). On the news Viking soared. Then Novo Nordisk struct...
The big pay off for Eli Lilly is still ahead
Back on August 18, I posted a buy for Eli Lilly (LLY). I said the stock was over-valued but would likely get more so. At the time Lilly shares were 46% over-valued according to Morningstar. Yesterday November 8, the stock was 68% over-valued. And even after a plunge...
Please WatchMy New YouTube Video: Quick Pick Eli Lilly
Today I posted my two-hundred-and-ninety-first YouTube Video: Quick Pick Eli Lilly (LLY) Want to grow your portfolio and protect it too? In the toughest investing market in 40 years? Grab my eBook, Your Best Investing Strategy for the Next 5 Years: Free download for...
Yesterday’s pick Eli Lilly pops today on Biogen’s good news on Alzheimer trial
Shares of Eli Lilly (LLY), a pick for my Jubak Pick’s Portfolio in a post yesterday, are up 8.89% today as of noon New York time, September 28, on news that an experimental Alzheimer’s drug from Biogen (BIIB) and Japan’s Eisai(ESALY) slowed cognitive and...
Adding Eli Lilly to my Jubak Picks Portfolio on diabetes drug approval, selling Incyte to balance
I’m extremely reluctant to add any stocks to any portfolios right now. There’s just too much near-term uncertainty and we remain locked in the grip of a pushing Bear Market. But I do want to upgrade my portfolios when possible to increase their future...
Fed’s Brainard sinks Treasuries and stocks with talk of more and faster inflation fighting
In remarks prepared for a Tuesday speech to the Minneapolis Federal Reserve Bank Federal Reserve Governor Lael Brainard said “Currently, inflation is much too high and is subject to upside risks. The committee is prepared to take stronger action if indicators of...
Yes, stocks bounced back today; No, everything is not all right with the markets or the economy
Yesterday the Standard & Poor’s 500 fell 1.14% and market leading stocks such as Applied Materials (AMAT) dropped 0.78%. Big drug stocks made up the only sector in the green as Pfizer (PFE) rose 2.59%,and AbbVie (ABBV) gained 1.23%. The fears yesterday were...
Adding Bristol-Myers Squibb to my Jubak Picks Portfolio tomorrow
As I noted in my posts over the weekend, I think that along with all the general volatility and the rotation away from high moment and higher price-to-earnings ratio technology stocks, the last week or so saw a rotation into “safe” haven stocks such as...
Please watch my new YouTube Video: Trend of the Week Big Pharma for Safety
I’m starting up my videos again–this time using YouTube as a platform. My sixty-ninth YouTube video “Trend of the Week Big Pharma for Safety” went up today. Please watch and subscribe to my YouTube channel. And like my video. Here’s the...
Why is the market up so strongly today? Look more to sector reasons and less to big picture bets
As of 2 p.m. New York time today the Standard & Poor’s 500 was up 2.99%. The Dow Jones Industrial Average was ahead 2.38%. The NASDAQ Composite had jumped a huge 4.16% and the NASDAQ 100 was up an even stronger 4.69%. The iShares MSCI Emerging Markets ETF...
Adding Pfizer to my Dividend Portfolio today
In Special Report: Meeting Your Retirement Challenge on my subscription site JubakAM.com, I suggested that when temporary factors created an opportunity to buy the shares of a solid, predictable, cash flow generating company, with a yield of 4% you should jump at the...
Incyte beats on earnings, revenue–but drops on lack of improved guidance
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
Analyst upgrade is catalyst for 6.17% jump in Acadia Pharmaceuticals today
Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock...
Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don’t think the gods of investing have repealed the laws of valuation. At...
Trump administration picks five coronavirus vaccine efforts to receive big government funding
The Trump administration has identified five companies that will get major government funding for the development of a coronavirus vaccine under Operation Warp Speed, the New York Times reported yesterday. The White House is expected to officially announce the names...
AbbVie continues its run–picks up momentum from Allergan results
Shares of AbbVie (ABBV) tacked on another 1.32% today to a close at $96 continuing a run that began back on January 31 at $81.02. The trend picked up momentum on February 7 after the company reported fourth quarter earnings with better than expected sales for its...
Merck continues to ride cancer drug Keytruda higher
Shares of Merck (MRK) closed up 3.50% today, October 29, after the company reported better than expected third quarter earnings. On a Non-GAAP basis earrings of $1.51 a share beat the Wall Street consensus by 27 cents a share. Revenue of $12.4 billion fell 6.7% year...
Selling Pfizer out of my Dividend Portfolio tomorrow on Dem’s proposed drug-pricing bill
Why introduce legislation that will dead on arrival in the Republican controlled Senate? Because House Speaker Nancy Pelosi and other Democrats know that controlling drug prices is extremely popular with voters. And a proposal that is a serious effort to lower drug...
Nektar’s plunge is a buying opportunity–so I’m adding more to my Volatility Portfolio
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid
Shares of Nektar Therapeutics (NKTR) have been bumping along between $32 and $34 for two months now, but the company continues to take steps to prepare for the likely August approval of NKTR-181, a new non-addictive opioid. Nektar has formed Inheris Biopharma, a...
Making Incyte #9 on my 10 most dangerous stocks for earnings season list–and #5 on my buy on any plunge list
Today on my JubakAM.com subscription site I made Incyte #9 in my 10 Most dangerous Stocks for Earnings Season Special Report–and #5 on my Buy on Any Plunge Bonus Special Report. Here’s what I wrote: “There’s a good chance that Incyte (INCY)...
Government action on drug prices seems far, far away
The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry’s business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today’s...
What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday’s close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big...
Buying Pfizer for my Dividend Portfolio
I’m going to take advantage of the selling in the market in general and in the drug sector in particular–on news of the asbestos liability at Johnson & Johnson and fears of the death of Obamacare (AKA the Affordable Care Act)–to buy Pfizer (PFE) in my Dividend...
Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte’s (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte’s Jakafi in combination...
Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It’s been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That’s likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of...
Incyte news continues to rebuild credibility of pipeline
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
Why Nektar is extremely oversold right now
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!